Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Key facts
- Where
- Calgary, Edmonton, Hamilton, London, Montreal, Oakville, Rimouski, Scarborough Village, St. Catharines, and Toronto, CanadaSee the 11 sites
- Phase
- Phase 3
Where in Canada
- University of Calgary, Peter Lougheed Centre Vascular ClinicCalgary, CanadaTaking people
- University of Alberta Mazankowski Heart InstituteEdmonton, CanadaTaking people
- Hamilton General HospitalHamilton, CanadaTaking people
- London Health Sciences CentreLondon, CanadaTaking people
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
- CIUSSS du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Cœur-de-MontréalMontreal, CanadaTaking people
- Vascular Health BronteOakville, CanadaTaking people
- Centre Intégré de Santé et de Services Sociaux du Bas-Saint-LaurentRimouski, CanadaTaking people
- Corcare Cardiovascular Research Inc.Scarborough Village, CanadaTaking people
- Niagara Health SystemSt. Catharines, CanadaTaking people
- Sunnybrook Research InstituteToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Population Health Research Institute
- Trial code
- NCT04774159
- Record updated
- 5 October 2026
- Original description
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.Read full original descriptionShow less
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
Inclusion: Age > 18 years; Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:; Intermittent claudication with ankle/arm blood pressure ratio* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. >1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR < 60 mL/min/1.73 m2); Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle/arm blood pressure ratio* (ABI ≤ 0.90) OR artery stenosis ≥ 50%; In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable; Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery; Leg or foot amputation for arterial vascular indications; Written or verbal informed consent from the patient.
Exclusion: Cirrhosis or severe chronic liver disease; Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin); eGFR < 30 mL/min/1.73 m2; Contraindication to colchicine; Long term requirement for colchicine for another clinical indication; Active diarrhoea; Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study; Patients who are deemed unlikely to return for follow-up; Patients with life expectancy < 1 year.